Ondine Announces Presentation of Positive Clinical Trial Results at the American...

Ondine Announces Presentation of Positive Clinical Trial Results at the
American Academy of Periodontology's 94th Annual Meeting

VANCOUVER, Sept. 5 /PRNewswire-FirstCall/ - Ondine Biopharma Corporation (TSX:
OBP; AIM: OBP), a medical technology company developing
photodisinfection-based products, today announced that a poster entitled
"Photodisinfection in the Treatment of Chronic Periodontitis" will be
presented by Company representatives at the American Academy of
Periodontology's (AAP) annual meeting. This year's AAP meeting is being held
at the Washington State Convention and Trade Center in Seattle, Washington on
September 6-9, 2008.
"We are pleased to have the opportunity to present photodisinfection to the
U.S. periodontal community," said Carolyn Cross, Ondine's President and CEO.
"This peer-reviewed poster highlights the positive results of the Company's
Multi-Centre Trial using its Photodisinfection System. Periodontal pockets
treated with photodisinfection (220mW laser plus photosensitizer) in addition
to scaling and root planing (SRP) yielded statistically significant reductions
in pocket depth (p=0.01) as well as increases in clinical attachment level
(p=0.002) when compared to pockets treated only with SRP."

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad
spectrum of bacterial, fungal and viral infections. The Company is focused on
developing and commercializing leading edge products utilizing its patented
light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is based in Vancouver, British Columbia,
Canada, with a research and development laboratory in Bothell, Washington,
USA, and an international office in St. Michael, Barbados. For additional
information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe",
"intend", "may", "expect" and other similar expressions, are forward-looking
statements that involve a number of risks and uncertainties. Factors that
could cause actual results to differ materially from those projected in the
Company's forward-looking statements include the following: market acceptance
of our technologies and products; our ability to obtain financing; our
financial and technical resources relative to those of our competitors; our
ability to keep up with rapid technological change; government regulation of
our technologies; our ability to enforce our intellectual property rights and
protect our proprietary technologies; the ability to obtain and develop
partnership opportunities; the timing of commercial product launches; the
ability to achieve key technical milestones in key products and other risk
factors identified from time to time in the Company's public filings.

The TSX Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.

SOURCE Ondine Biopharma Corporation

Carolyn Cross, President and Chief Executive Officer, Ondine Biopharma
Corporation, (604) 669-0555, ccross@ondinebiopharma.com; Adam Peeler, Investor
Relations, The Equicom Group Inc., (416) 815-0700 ext. 225,
apeeler@equicomgroup.com; Canaccord Adams Ltd, Nominated Adviser & Broker,
Neil Johnson, Ryan Gaffney, +4420 7050 6500